PFE vs TTRX
PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas. TTRX: Turn Therapeutics is a clinical-stage biotechnology company developing GX-03, a non-systemic topical immunomodulator targeting atopic dermatitis and other inflammatory skin conditions.
Side-by-side fundamentals
| Metric | PFE | TTRX | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $29.85 | $10.15 | |
| Market cap | $170.1B | $302M | |
| P/E as of 2026-10-21 | 39.28 | n/a | |
| Net margin FY2025, SEC XBRL | +12.4% | n/a | |
| ROE FY2025, SEC XBRL | +9.0% | -68.2% | PFE higher |
| ROA FY2025, SEC XBRL | +3.7% | -26.3% | PFE higher |
| Debt / equity | 0.74 | 8.83 | PFE lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -1.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -14.8% | n/a | |
| Dividend yield as of 2026-09-02 | +6.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 11 | 0 | PFE higher |
| Beta as of 2026-09-02 | 0.38 | 1.15 | |
| 1-year return as of 2026-10-21 close | +20.1% | +114.1% | TTRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.